Nicardipine is more effective than esmolol at preventing blood pressure increases during emergence from total intravenous anesthesia

Department of Anesthesiology and Pain Medicine, *Seoul National University Bundang Hospital, Seongnam, †Seoul National University Hospital, Seoul, Korea

Sang-Hyun Park*, Sang-Hwan Do*, Hye-Young Shin†, Young-Tae Jeon*, Jung-Won Hwang*, and Sung-Hee Han*

Background: This prospective, randomized, double-blind study was undertaken to compare prophylactic nicardipine infusion with esmolol infusion to determine their effects on the control of hemodynamic response during emergence from total intravenous anesthesia (TIVA) with propofol and remifentanil.

Methods: One hundred and thirty two patients undergoing thyroidectomy were divided randomly into 3 groups. About 10 minutes before the end of surgery, propofol was stopped in all the patients and nicardipine group (n = 44) received a continuous infusion of 2 μg/kg/min nicardipine during emergence from TIVA, esmolol group (n = 44) received 250 μg/kg/min esmolol, and placebo group received 10−14 ml/hr of isotonic saline until 15 min after transfer to a postanesthesia care unit (PACU). Hemodynamic profiles were measured every minute throughout the study period.

Results: MBP was significantly lower in the nicardipine group than in the esmolol group (P < 0.05) from 10 min after PACU transfer until 10 min after study drug infusion stop. On the other hand, HR was significantly lower in the esmolol group than in the nicardipine group from 6 min after drug infusion.

Conclusions: Nicardipine infusion attenuated blood pressure increases more effectively than esmolol infusion during emergence from TIVA. (Korean J Anesthesiol 2009; 57: 597∼603)

Key Words: Esmolol, Intravenous infusions, Nicardipine, Total intravenous anesthesia.

INTRODUCTION

Emergence from general anesthesia and tracheal extubation is often accompanied with tachycardia and hypertension [1]. It has been reported that patients experience 37%, 50% and 55% increases in systolic blood pressure (BP), diastolic BP, and heart rate (HR), respectively, during tracheal extubation [2]. Accordingly, it is imperative that these hemodynamic responses be controlled in patients with unstable cardiovascular status to prevent complications.

Total intravenous anesthesia (TIVA) with propofol and remifentanil allows rapid and predictable titration of anesthesia, and swift consciousness and respiration recovery even after prolonged anesthesia. However, despite these potential advantages of TIVA, postoperative complications such as hypertension may be common [3]. In addition, the incidence of hypertension after TIVA has been reported to be higher than inhalation anesthesia with fentanyl [4]. Several studies have addressed the effectiveness of esmolol or nicardipine with respect to the blunting of hemodynamic alterations associated with emergence from anesthesia [5-8].

This prospective, randomized and double-blind study was designed to compare the hemodynamic effects of nicardipine and esmolol infusions during emergence from TIVA with propofol and remifentanil.
MATERIALS AND METHODS

After obtaining approval from the Institutional Review Board of Seoul National University Bundang Hospital and written informed consent from all study subjects, 132 adult patients aged 18—70 with American Society of Anesthesiologists physical statuses 1 or 2 were enrolled in this study. The enrollment criteria applied were scheduled total thyroidectomy under general anesthesia. Patients with a cardiovascular or pulmonary disorder, or diabetes were excluded.

The patients received 0.04 mg/kg i.v. midazolam premedication before entering the operating room. Electrocardiography, noninvasive blood pressure monitoring and pulse oximetry were established. Electrodes were placed on the forehead to monitor bispectral index (BIS) (A-2000 BIS® monitor, Aspect® Medical Systems, Natick, MA, USA). Preinduction mean blood pressure (MBP) and heart rate (HR) were defined as the average of three repeated measures obtained one day before surgery. Anesthesia was induced with target-controlled infusion (TCI) using an Orchestra® infusion pump system (Fresenius Kabi, Brezins, France). Patients received propofol 4 μg/ml and remifentanil 4 ng/ml. Muscle paralysis was achieved with vecuronium 0.15 mg/kg prior to tracheal intubation. Subsequently, lungs were ventilated with oxygen and medical air (FiO₂ 0.5) and subsequent mifentanil 4 ng/ml. Muscle paralysis was achieved with vecuronium 0.15 mg/kg prior to tracheal intubation. Subsequently, lungs were ventilated with oxygen and medical air (FiO₂ 0.5), tidal volume was adjusted to maintain an end-tidal dioxide partial pressure between 4.3 and 4.7 kPa.

Anesthesia was maintained using propofol and remifentanil. Effect-site target concentrations of propofol were adjusted to maintain BIS between 40—50 and those of remifentanil were adjusted using clinical signs and hemodynamic measurements. Inadequate anesthesia was defined as an increase in MBP or HR of more than 20% of the preanesthetic value. If inadequate anesthesia or hypotension (systolic BP < 85 mmHg or mean BP < 60 mmHg) in all groups. Five, 10 min after study medication infusion, remifentanil infusion was discontinued and then neuromuscular blockade was reversed with pyridostigmine 0.3 mg/kg and glycopyrrolate 0.01 mg/kg. All patients’ tracheas were carefully extubated when they were able to obey commands and spontaneous respiration was deemed adequate. Baseline MBP and HR were defined as the values just before study drug infusion. BIS, HR and BP were measured every minute for up to 10 minutes from study drug infusion and times to extubation were recorded. The hypotensive patients (systolic BP < 85 mmHg or mean BP < 60 mmHg) and patients with bradycardia (HR < 45 bpm) after study drug infusion were excluded from analysis. The total amounts of propofol and remifentanil infused during operations were recorded.

Five, 10 and 15 min after transfer to PACU, MBP and HR were recorded without pain control. Subsequently, ketorolac (30 mg) was administered when patients complained of pain and a fixed dose of intermittent nicardipine (1 mg) for hypertension (systolic BP > 160 mmHg) in all groups. Five, 10 min after discontinuing study medication, immediately and 6 hour after arrival in a ward, MBP and HR were recorded. Rate-pressure products (RPP) were calculated by multiplying systolic BP by HR.

Sample size was determined using our pilot study results obtained from 40 patients and were based on the assumption that a 15 mmHg difference in MBP is clinically relevant. Power analysis suggested that a minimum of 38 patients per group would be required for a β = 0.1 and α = 0.05. To compensate for potential dropouts, we enrolled 44 patients in each of the three groups. Data are presented as mean values ± SD unless noted otherwise. The patient’s age, weight, height, MBP, HR, BIS, time to extubation and total doses of propofol or remifentanil were analyzed using one-way analysis of variance, and Scheffe’s method was used for multiple comparison.
Table 1. Demographic Characteristics and amounts of Anesthetics Used

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n = 44)</th>
<th>Nicardipine (n = 43)</th>
<th>Esmolol (n = 42)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M/F)</td>
<td>11/32</td>
<td>11/32</td>
<td>8/34</td>
<td>0.715</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>45 ± 11</td>
<td>48 ± 11</td>
<td>48 ± 11</td>
<td>0.416</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>61 ± 10</td>
<td>65 ± 10</td>
<td>61 ± 9</td>
<td>0.217</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>161 ± 8</td>
<td>161 ± 8</td>
<td>160 ± 7</td>
<td>0.529</td>
</tr>
<tr>
<td>Total dose of propofol (mg)</td>
<td>890 ± 240</td>
<td>861 ± 266</td>
<td>883 ± 251</td>
<td>0.878</td>
</tr>
<tr>
<td>Total dose of remifentanil (μg)</td>
<td>759 ± 254</td>
<td>719 ± 219</td>
<td>712 ± 259</td>
<td>0.691</td>
</tr>
<tr>
<td>Mean time to extubation after drug infusion (min)</td>
<td>9.1 ± 0.7</td>
<td>9.0 ± 0.6</td>
<td>9.1 ± 0.8</td>
<td>0.85</td>
</tr>
</tbody>
</table>

Data are mean ± SD or numbers (n). Patients in the nicardipine and esmolol groups receive a continuous infusion of 2 μg/kg/min nicardipine or 250 μg/kg/min esmolol respectively during emergence from total intravenous anesthesia, while the placebo group receives 10−14 ml/hr normal saline.

Table 2. Rescue Drugs Used for Pain, Bradycardia and Hypertension

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n = 44)</th>
<th>Nicardipine (n = 43)</th>
<th>Esmolol (n = 42)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketorolac 30 mg IVS</td>
<td>13</td>
<td>13</td>
<td>14</td>
</tr>
<tr>
<td>Atropine 0.5 mg IVS</td>
<td>0</td>
<td>0</td>
<td>1*</td>
</tr>
<tr>
<td>Nicardipine 1 mg IVS</td>
<td>4</td>
<td>0</td>
<td>3</td>
</tr>
</tbody>
</table>

Data are numbers of patients (n). The nicardipine and esmolol groups receive a continuous infusion of 2 μg/kg/min nicardipine or 250 μg/kg/min esmolol during emergence from total intravenous anesthesia, while the placebo group receives 10−14 ml/hr normal saline. *One patient suffers from bradycardia after esmolol infusion. This case is excluded from the analysis of mean blood pressure and heart rate profiles.

RESULTS

Of the 132 enrolled patients, 3 patients were excluded from the analysis because of hypotension (1 in the nicardipine group and 1 in the esmolol group) and bradycardia (1 in the esmolol group). Demographic data for the remaining 129 patients are shown in Table 1. No significant differences were apparent among the esmolol, nicardipine, and placebo group with regard to demographic characteristics or anesthetic drug requirements. The number of patients administered with atropine, post-operative ketorolac, and nicardipine (1 mg) were also comparable in the three groups (Table 2).

Pre-induction and baseline MBP values were similar among the three groups (Fig. 1). Compared to baseline, increases in
MBP were observed from 10 min after infusion start in nicardipine group, 7 min in esmolol and in placebo group. From 10 min after transfer to PACU until 10 min after infusion stop, MBP was significantly lower in the nicardipine group than in the esmolol group (P < 0.05).

Pre-induction and baseline HR values were comparable among the three groups (Fig. 2). Compared to baseline, increases in HR were observed from 10 min after infusion start in esmolol group, 7 min in nicardipine and in placebo group. HR was significantly lower in the esmolol group than in the nicardipine group from 6 min after drug infusion. No differences in HR were observed between the nicardipine and placebo group at any time.

RPP was significantly lower in the esmolol group than in the placebo group from 8 min after drug infusion (Fig. 3), but the esmolol and nicardipine groups were comparable. BIS values were similar at each time point among the three groups (Fig. 4).

**DISCUSSION**

Clinical studies have demonstrated that emergence from TIVA with propofol and remifentanil as compared with balanced anesthesia using inhalation anesthetics and opioid, is accompanied by an increased incidence of hypertension requiring antihypertensive medication to maintain MBP within 20% of baseline [4,11]. Moreover, a higher incidence of hypertension after remifentanil-based anesthesia has been previously described and was attributed to inadequate analgesia after stopping remifentanil infusion [12]. Therefore, anesthesiologists using TIVA should consider employing antihypertensive therapy more liberally at around the end of surgical procedures.

The recommended infusion rate of esmolol is reported to be $200 - 300 \mu g/kg/min$ [10,13] and that of nicardipine to be $1 - 3 \mu g/kg/min$ [9,14]. Thus, we chose median values of these ranges as infusion rates for this study (esmolol 250 $\mu g/kg/min$, nicardipine 2 $\mu g/kg/min$). A small loading dose (e.g., esmolol...
Fig. 4. Perioperative changes in electroencephalographic (EEG) bispectral index (BIS) in the three groups from baseline (mean ± SD). The nicardipine and esmolol groups receive a continuous infusion of 2 μg/kg/min nicardipine or 250 μg/kg/min esmolol during emergence from total intravenous anesthesia, while the placebo group receives 10−14 ml/hr normal saline. Dotted line: at the end of surgery, remifentanil infusion is discontinued and the neuro-muscular blockade is reversed. No differences are evident among the three groups. Ext: extubation, B: before study drug infusion start, 1 min (T1), 2 min (T2), 3 min (T3), 4 min (T4), 5 min (T5), 6 min (T6), 7 min (T7), 8 min (T8), 9 min (T9), 10 min (T10) after study drug infusion.

500 μg/kg/min or nicardipine 5 μg/kg/min) has been used in most investigations involving endotracheal intubation or controlled hypotension. However, this loading dose was omitted in the present study because it has been associated with symptomatic hypotension [15] and the purpose of this study was to prevent hypertension, not to induce hypotension.

In the esmolol group, the hypotensive effect of esmolol was not obvious. Compared with the placebo group, MBP was significantly lower at just one time point (10 min after drug infusion, Fig. 1). In addition, 3 patients in the esmolol group required bolus doses of nicardipine due to uncontrolled hypertension despite esmolol infusion in the PACU. These findings are contrary to previous investigations [6,16] in which an esmolol bolus or infusion attenuated HR and BP increases after tracheal extubation. The mechanism underlying these different hemodynamic responses to esmolol appear to be associated with different cardiovascular statuses, patient characteristics (e.g., young vs. old), or different modes of anesthesia (TIVA vs. inhalation anesthesia). During TIVA, propofol causes peripheral vasodilatation [17] and after its discontinuation, there might be a rebound increase in systemic vascular resistance. In addition, esmolol is associated with a profound decrease in cardiac output and reflex increase in systemic vascular resistance [18]. Taken together, the above suggests that esmolol may be ineffective at attenuating BP increases during emergence from TIVA.

In this study, MBP was significantly lower in the nicardipine group than in the other two groups until 10 min after terminating drug infusion, and it was restored in the ward. This finding is consistent with a previous investigation in which time to baseline BP restoration after nicardipine infusion was approximately 20 min [19]. In addition, the use of nicardipine infusion requires caution when administration is prolonged (about 270 ± 20 min) because nicardipine may have a cumulative effect, which may cause resistance to vasopressors [20]. In the present study, the duration of nicardipine administration was 25 min, which is not associated with accumulation.

No differences in HR were observed between the nicardipine and the placebo group at any time point in this study. Diverse results have been reported regarding the effect of nicardipine on HR. A nicardipine bolus is known to cause tachycardia at emergence and tracheal extubation, because of a reduced systemic vascular resistance and reflex tachycardia [7,8]. However, other investigators reported that bolus nicardipine administered to anesthetized patients did not increase HR [21], which may have been due to an attenuation of reflex sympathetic activity. In addition, it has been reported that no change in HR occurred during long-term hypotensive anesthesia with nicardipine infusion [20]. The reasons for these different hemodynamic responses to nicardipine seem to be associated with different modes of dosing (i.e., single bolus vs. continuous infusion without a loading dose) and/or different modes of anesthesia (inhalational anesthesia vs. TIVA).

Myocardial oxygen consumption (MVO$_2$) was not measured in this study, but RPP is a good correlate of overall MVO$_2$ [22]. In patients with myocardial ischemia, esmolol was found to effectively reduce HR and BP, and thereby decrease RPP [23]. In our study, RPP was significantly lower in the esmolol group than in the placebo group from 8 min after drug infusion, but was comparable between esmolol and nicardipine group. In addition, it has been reported that the greater selectivity of nicardipine for the coronary vasculature can increase myocardial oxygen supply [24]. Therefore, nicardipine can be administered safely without the risk of RPP increase in patients with ischemic heart disease to control BP. Nicardipine can also induce favorable cerebrovascular changes in stroke
patients. These include cerebral vasospasm reversal, cerebral blood flow augmentation, and thus oxygen delivery, and the inhibition of platelet aggregation [24]. Therefore, it makes sense to administer nicardipine before emergence from TIVA to reduce the cerebrovascular risk in patients with cerebrovascular disease.

At the end of surgery, intravenous patient-controlled analgesia (PCA) infusion was not applied in this study, because post-thyroideectomy pain is considered to be relatively mild. Moreover, skin infiltration with local anesthetic such as ropivacaine, as administered in this study, should decrease postoperative pain [25]. Although intraoperative esmolol is associated with decreased requirements in postoperative opioids [26], no significant difference was observed among the three groups with respect to rescue analgesic requirements. In addition, we were set on preserving the double-blind design of this study. The difficulties associated with blinding investigators with respect to esmolol infusion has been previously described [27], as it was expected that a decrease in HR in response to an esmolol loading dose would readily identify patients on esmolol.

In conclusion, the present study demonstrates that esmolol infusion (250 μg/kg/min) during emergence from TIVA attenuated HR increase but only marginally affected BP increases, whereas nicardipine infusion (2 μg/kg/min) mainly attenuated BP increase but did not affect HR or RPP. Accordingly, nicardipine infusion was found to be more effective than esmolol infusion at attenuating BP increases during emergence from TIVA with propofol and remifentanil.

REFERENCES


